Inclusion Criteria:

          -  Male or female patients age ≥ 18 years

          -  Pathologic documentation of clear cell renal cell carcinoma

          -  Disease that is resistant or refractory to standard of care

          -  ECOG Performance Status < 2

          -  Most recent tissue biopsy demonstrates PSMA expression by immunohistochemical staining

          -  Adequate bone marrow function measured within 7 days prior to first infusion of G-202
             (absolute peripheral granulocyte count > 1500 cells/m3; platelet count > 100,000
             cells/m3)

          -  Adequate hepatic function measured within 7 days prior to first infusion of G-202
             (Albumin ≥ 2.8 g/dL; AST and ALT ≤ 5 x ULN; Total bilirubin <2 mg/dL)

          -  Adequate renal function measured within 7 days prior to first infusion of G-202
             (Proteinuria level ≤ 2 by urine dipstick; Serum creatinine ≤1.5 x ULN)

          -  Normal coagulation profile measured within 14 days prior to first infusion of G-202
             (INR ≤ 2.3; aPTT ≤ 1.5 X ULN)

          -  No history of substantial non-iatrogenic bleeding diatheses. Use of anti-coagulants is
             limited to local use only (for control of central line patency)

          -  Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study and are willing to participate in the study

          -  Females of child-bearing potential and males with female partners of child-bearing
             potential must be willing to use acceptable methods of contraception to avoid
             pregnancy (for example, oral, injectable, or implantable hormonal contraceptive; tubal
             ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized
             partner) beginning before the first infusion of G-202 and for 3 months after the last
             infusion of G-202

        Exclusion Criteria:

          -  Uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric disorder

          -  HIV positivity or history of chronic hepatitis B or C infection

          -  Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or history of
             congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless a 2D
             echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months of
             enrollment demonstrates a left ventricular ejection fraction >45%

          -  History of another malignancy within the previous 5 years other than curatively
             treated non-melanoma skin cancer or or intraepithelial carcinoma of the cervix

          -  Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1
             week of first G-202 treatment

          -  Treatment, chemotherapy, radiation therapy, immunotherapy, or investigational drug for
             the patient's renal cell cancer within 28 days prior to first infusion of G-202

          -  Currently requiring systemic administration of antibiotics or chronic administration
             of anti-viral agents

          -  Use of anti-coagulants is limited to local use for control of central line patency

          -  History or evidence of cardiac risk, including corrected QT interval on screening ECG
             > 470 msec, clinically significant uncontrolled arrhythmias or arrhythmia requiring
             treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular
             tachycardia, history of acute coronary syndromes within 6 months prior to the first
             dose of study therapy (including myocardial infarction and unstable angina, coronary
             artery bypass graft, angioplasty, or stenting), any history of congestive heart
             failure with most recent ejection fraction < 45%

          -  Uncontrolled cardiac or coronary artery disease

          -  Uncontrolled hypertension (mean systolic BP ≥ 160 mm Hg and/or mean diastolic BP ≥ 100
             mm Hg on 3 determinations 5 minutes apart while on 2 anti-hypertensive agents) or
             hypertension requiring treatment with more than 2 anti-hypertensive agents.

          -  Severe or uncontrolled medical disease, including uncontrolled diabetes, congestive
             heart failure, chronic renal disease or chronic pulmonary disease

          -  Severe gastrointestinal bleeding within 12 weeks of treatment with G-202

          -  Requirement for chronic use of medications known to be strong inhibitors or inducers
             of cytochrome (CYP3A4) iso-enzymes (Appendix 3) Note: If patients can stop receiving
             these medications, CYP3A4 inhibitors should be discontinued at least 7 days prior to
             starting treatment with G-202

          -  Known hypersensitivity to any study drug component including thapsigargin derivatives,
             polysorbate 20, or propylene glycol

          -  Any other condition, including concurrent medical condition, social circumstance or
             drug dependency, which in the opinion of the investigator could compromise patient
             safety and/or compliance with study requirements